INPP5A/HLA-G1/IL-10/MMP-21 Axis in Progression of Esophageal Squamous Cell Carcinoma
Iranian Biomedical Journal · 01.10.2022 · 26 (6) · 440-453
DOI: 10.52547/ibj.3716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Biomedical Journal, online erschienen am 01.10.2022. Verfasst von Sima Ardalan Khales und 3 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.
Zitieren
APA
Ardalan Khales, S., Aarabi, A., Abbaszadegan, M. R., & Forghanifard, M. M. (2022). INPP5A/HLA-G1/IL-10/MMP-21 Axis in Progression of Esophageal Squamous Cell Carcinoma. Iranian Biomedical Journal, 26(6), 440-453. https://doi.org/10.52547/ibj.3716
Vancouver
Ardalan Khales S, Aarabi A, Abbaszadegan MR, Forghanifard MM. INPP5A/HLA-G1/IL-10/MMP-21 Axis in Progression of Esophageal Squamous Cell Carcinoma. Iranian Biomedical Journal. 2022;26(6):440-453. doi:10.52547/ibj.3716
BibTeX
@article{ArdalanKhales2022,
author = {Ardalan Khales, Sima and Aarabi, Azadeh and Abbaszadegan, Mohammad Reza and Forghanifard, Mohammad Mahdi},
title = {INPP5A/HLA-G1/IL-10/MMP-21 Axis in Progression of Esophageal Squamous Cell Carcinoma},
journal = {Iranian Biomedical Journal},
year = {2022},
volume = {26},
number = {6},
pages = {440--453},
doi = {10.52547/ibj.3716}
}
EUVIMED